ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Equal access, unequal outcomes? racial disparities in mortality between black and white women with breast cancer: a 10-year systematic review and meta-analysis.Journal of cancer survivorship : research and practice · 2026Pooled it
- Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Systematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations.British journal of cancer · 2025Pooled it
- Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2018Pooled it
- Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA).JCO global oncology · 2026Trial
- Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial.Breast cancer research and treatment · 2025Trial
- Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.Breast cancer research and treatment · 2024Trial
- Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.Annals of surgical oncology · 2023Trial
- Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.JNCI cancer spectrum · 2021Trial
- Self-reported racial and ethnic discrimination in patient-provider interactions and the initiation of adjuvant therapies for breast cancer in the pathways study.Breast cancer research and treatment · 2026Article
- Financial hardship and mental health among cancer survivors: examining the moderating role of race/ethnicity.Journal of cancer survivorship : research and practice · 2026Article
- Evaluating the association between upstream perceived individual and neighborhood determinants of health and intensity of breast cancer screening.American journal of epidemiology · 2026Article
- Racial differences in biomarkers, treatment, and outcomes in HR+/HER2- metastatic breast cancer in the United States.NPJ breast cancer · 2026Article
- Guideline-concordance along the cancer care continuum and breast cancer mortality by race and ethnicity: a SEER-Medicare study.Cancer causes & control : CCC · 2026Article
- Racial Disparities in Psychoneurological Symptoms and Health-Promoting Behaviors Among Breast Cancer Survivors: A Two-Year Longitudinal Study.Oncology nursing forum · 2026Article
- Assessing barriers to genomic testing in breast cancer among diverse patients: a qualitative community-engaged research study.Breast cancer research and treatment · 2025Article
- Differences in breast cancer outcomes amongst Caribbean born women in Florida, USA-a population-based analysis.Lancet regional health. Americas · 2025Article
- Annals of Surgical Oncology Landmark Series Disparities in Surgical Oncology: Breast Cancer.Annals of surgical oncology · 2025Review
- Racial and Ethnic Differences in Diabetes Care Quality in A National Sample of Cancer Survivors Relative to Non-Cancer Controls.Journal of racial and ethnic health disparities · 2025Article
- Geospatial disparities, health system factors, and breast cancer care quality.JNCI cancer spectrum · 2025Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To estimate the contribution of differences in demographics, comorbidity, insurance, tumor characteristics, and treatment to the overall mortality disparity between nonelderly black and white women diagnosed with early-stage breast cancer. Patients and Methods Excess relative risk of all-cause death in black versus white women diagnosed with stage I to III breast cancer, expressed as a percentage and stratified by hormone receptor status for each variable (demographics, comorbidity, insurance, tumor characteristics, and treatment) in sequentially, propensity-scored, optimally matched patients by using multivariable hazard ratios (HRs). Results We identified 563,497 white and black women 18 to 64 years of age diagnosed with stage I to III breast cancer from 2004 to 2013 in the National Cancer Data Base. Among women with hormone receptor-positive disease, who represented 78.5% of all patients, the HR for death in black versus white women in the demographics-matched model was 2.05 (95% CI, 1.94 to 2.17). The HR decreased to 1.93 (95% CI, 1.83 to 2.04), 1.54 (95% CI, 1.47 to 1.62), 1.30 (95% CI, 1.24 to 1.36), and 1.25 (95% CI, 1.19 to 1.31) when sequentially matched for comorbidity, insurance, tumor characteristics, and treatment, respectively. These factors combined accounted for 76.3% of the total excess risk of death in black patients; insurance accounted for 37.0% of the total excess, followed by tumor characteristics (23.2%), comorbidities (11.3%), and treatment (4.8%). Results generally were similar among women with hormone receptor-negative disease, although the HRs were substantially smaller. Conclusion Matching by insurance explained one third of the excess risk of death among nonelderly black versus white women diagnosed with early-stage breast cancer; matching by tumor characteristics explained approximately one fifth of the excess risk. Efforts to focus on equalization of access to care could substantially reduce ethnic/racial disparities in overall survival among nonelderly women diagnosed with breast cancer.
Indexed as
Identifiers
29035645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.